4.54
-0.17(-3.61%)
Currency In USD
| Previous Close | 4.71 |
| Open | 4.7 |
| Day High | 4.77 |
| Day Low | 4.51 |
| 52-Week High | 26.62 |
| 52-Week Low | 3.85 |
| Volume | 267,924 |
| Average Volume | 767,200 |
| Market Cap | 162.75M |
| PE | -2.13 |
| EPS | -2.13 |
| Moving Average 50 Days | 8.64 |
| Moving Average 200 Days | 14.44 |
| Change | -0.17 |
If you invested $1000 in BioAge Labs, Inc. (BIOA) since IPO date, it would be worth $247.95 as of February 05, 2025 at a share price of $4.54. Whereas If you bought $1000 worth of BioAge Labs, Inc. (BIOA) shares 5 months ago, it would be worth $247.95 as of February 05, 2025 at a share price of $4.54.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioAge Labs Announces Company Updates on APJ, NLRP3, and Platform Programs
GlobeNewswire Inc.
Jan 28, 2025 2:00 PM GMT
Advancement of next-generation APJ agonists with discontinuation of azelaprag Nomination of NLRP3 inhibitor BGE-102 as a development candidate, with initial Ph1 clinical data anticipated by end of 2025 Expansion of discovery efforts based on insights
BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions
GlobeNewswire Inc.
Dec 18, 2024 2:00 PM GMT
Collaboration will leverage BioAge's differentiated human longevity data and platform and Novartis expertise in the biology of physical exercise to identify drug targets to treat diseases related to aging Novartis to pay up to $20M comprising upfront
BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity
GlobeNewswire Inc.
Dec 06, 2024 9:35 PM GMT
Decision follows observations of liver transaminitis without clinically significant symptoms in some subjects on azelaprag Company will evaluate data from patients enrolled to date and share updated plans for azelaprag in Q1 2025 In parallel to evalu